TAIJI GROUP(SH:600129) Ge Long Hui A P P·2025-09-09 08:52Core Viewpoint - Taiji Group's subsidiary, Fuling Pharmaceutical, has received approval from the National Medical Products Administration for clinical trials of Semaglutide injection, which is significant for treating type 2 diabetes and weight management [1] Group 1: Company Developments - Fuling Pharmaceutical has been granted a clinical trial approval for Semaglutide injection, a GLP-1 receptor agonist [1] - The approved indication is for blood sugar control in adult patients with type 2 diabetes who have inadequate control despite treatment with metformin and/or sulfonylureas [1] - The drug is also indicated for reducing the risk of major cardiovascular adverse events in adult patients with type 2 diabetes and cardiovascular disease [1]